Skip to main content

Advertisement

Table 2 Odds ratios with 95% confidence intervals for breast cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and over the counter nonsteroidal anti-inflammatory drugs (OTC NSAIDS).

From: Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

Compound Number of Cases Number of Controls Age Adjusted OR (95% CI) Multivariate ORd(95% CI)
None/Infrequent Use a 262 453 1.00 1.00
COX-2 Inhibitors b 10 52 0.31 (0.16–0.64) 0.29 (0.14–0.59)
OTC NSAIDs c     
   Aspirin 15 40 0.51 (0.27–0.98) 0.49 (0.26–0.94)
   Ibuprofen/Naproxen 11 52 0.37 (0.18–0.71) 0.37 (0.18–0.72)
   Acetaminophen 8 16 0.92 (0.39–2.20) 1.02 (0.39–2.20)
   Baby Aspirin 17 36 0.82 (0.40–1.40) 0.77 (0.42–1.41)
  1. aNo use of any NSAID or analgesic or infrequent use of no more than one pill per week for less than one year;
  2. bCOX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, and meloxicam used daily for two years or more.
  3. cOver the counter (OTC) NSAIDs/analgesics used at least two times per week for two years or more.
  4. dMultivariate odds ratios are adjusted for continuous variables (age and body mass) and categorical variables (parity, menopausal status, family history, smoking, and alcohol intake).